NCT05461768View on ClinicalTrials.gov

A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 9, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Breast CancerLocally Advanced or Metastatic Solid Tumor
Interventions
DRUG

BL-M07D1

Administration by intravenous infusion

Trial Locations (7)

510120

RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong

Unknown

RECRUITING

Fujian Cancer Hospital, Fuzhou

RECRUITING

Dongguan People's Hospital, Dongguan

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

RECRUITING

Jinan Central Hospital, Jinan

RECRUITING

Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

SystImmune Inc.

INDUSTRY

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT05461768 - A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors | Biotech Hunter | Biotech Hunter